Skip to main content

Advertisement

Fig. 5 | BMC Cancer

Fig. 5

From: Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma

Fig. 5

ADGRE5 (alias CD97) protein expression in cell lines and patient tumor samples. a Proteomic analysis of ADGRE5, BYSL and NPM1 level in BL (i), DLBCLneg (ii) and DLBCLpos (iii) cell lines. b Schematic model of largest ADGRE5 isoform EGF (1,2,3,4,5), Arg-Gly-Asp integrin-binding motif (RGD), GPCR-autoproteolysis-inducing domain (GAIN), epidermal growth factor domain (EGF), and nucleoside position of potential N-glycosylation sites are indicated. c Western Blot analysis of expression of ADGRE5, BYSL, NMP1 and endogenous control ß-actin and GAPDH in selected cell lines. d Immunohistochemical (IHC) staining of ADGRE5 protein in BL, DLBCLpos and DLBCLneg cell lines and FFPE tumor tissue samples. e Overview of ADGRE5 staining FFPE tumor tissue samples and supplementary information

Back to article page